Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study.
- Author:
Young Woo JEON
1
;
Jae Ho YOON
;
Sung Eun LEE
;
Ki Seong EOM
;
Yoo Jin KIM
;
Hee Je KIM
;
Seok LEE
;
Chang Ki MIN
;
Jong Wook LEE
;
Woo Sung MIN
;
Seok Goo CHO
Author Information
- Publication Type:Original Article
- Keywords: Autoimmune diseases; Arthritis, rheumatoid; Lymphoproliferative disorders; Lymphoma, non-Hodgkin; Methotrexate
- MeSH: Age of Onset; Arthritis, Rheumatoid; Asian Continental Ancestry Group; Autoimmune Diseases; Clinical Study*; Cohort Studies; Disease-Free Survival; Drug Therapy; Follow-Up Studies; Humans; Korea; Lymphoma; Lymphoma, Non-Hodgkin*; Lymphoproliferative Disorders; Methotrexate; Mortality; Retrospective Studies*
- From:The Korean Journal of Internal Medicine 2016;31(5):944-952
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Recently, large cohort studies regarding associations between autoimmune disease and lymphomas have been reported in a few Western countries. However, Asian data concerning autoimmune-related lymphomas are limited. Therefore, we evaluated the clinical characteristics and prognostic factors of patients with autoimmune disease-related non-Hodgkin lymphoma (NHL) in a single center in Korea. METHODS: We analyzed the data from 11 patients with autoimmune-related NHL. Patients were categorized into two groups, those with rheumatoid arthritis (RA) and those with non-RA-related NHL. Then patients were re-categorized into a group with methotrexate (MTX) usage and a MTX non-usage group. Histological subtype, MTX duration, autoimmune disease duration, treatment modalities, and other data were collected and analyzed. RESULTS: Our study revealed that older RA patients have a greater likelihood of occurrence of NHL (p = 0.042). We confirmed that MTX duration and cumulative dose of MTX have no significant correlation with autoimmune disease and NHL (p = 0.073). In the management of autoimmune disease-related NHL, all patients were directly treated with systemic chemotherapy instead of employing a wait and watch approach. Overall survival (OS) and progression-free survival (PFS) in all autoimmune disease-related NHL were 100% and 87.5%, with no treatment-related mortality during the 2-year follow-up period of our study. CONCLUSIONS: Our study suggests that patients with RA-NHL are characterized by older age at onset compared to those with non-RA-NHL. Also considering of OS and PFS, intensive treatment strategy instead of delayed watchful managements may be required for autoimmune disease-related NHL including of old age group.
